Interrupted Identities: Autologous Stem Cell Transplant in Patients With Multiple Myeloma
نویسندگان
چکیده
منابع مشابه
Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma
Autologous stem cell transplant (ASCT) is the standard of care in transplant-eligible multiple myeloma patients and is associated with significant improvement in progression-free survival (PFS), complete remission rates (CR), and overall survival (OS). However, majority of patients eventually relapse, with a median PFS of around 36 months. Relapses are harder to treat and prognosis declines wit...
متن کاملComplete response after autologous stem cell transplant in multiple myeloma
We evaluated long-term outcome of patients achieving complete response (CR) after autologous stem cell transplantation (ASCT) for multiple myeloma. Between April 1990 and June 2012 191 patients underwent ASCT. The median age was 53 years (range, 26-68 years), 135 were men. Pretransplant, patients received induction therapy with VAD (vincristine, doxorubicin, dexamethasone; n = 77), novel agents...
متن کاملSequential, Autologous Hematopoietic Stem Cell Transplant Followed by Renal Transplant in Multiple Myeloma
A 30-year-old female was symptomatic with headache, fatigue, and weakness since October 2011 and was told to have anemia. In January 2012, she was admitted outside with pulmonary edema. Investigations revealed advanced azotemia, anemia, and hypercalcemia. Urine showed 2 + proteins and 30-35 red blood cells. There was no history of oral ulcers, rash, Raynaud's phenomenon, or hemoptysis. She was ...
متن کاملISS Versus R-ISS for Risk Stratification of Multiple Myeloma Patients undergoing Autologous Stem Cell Transplant
Rafael Ríos-Tamayo1,2,3,4, Antonio Romero2, José Manuel Puerta2, Pedro Antonio González2, Elisa López-Fernández2, Lucía Moratalla2, Juan Sáinz1,2,3,4, Manuel Jurado1,2,3,4 1Monoclonal Gammopathies Unit, University Hospital Virgen de las Nieves, Granada, Spain 2Department of Hematology, University Hospital Virgen de las Nieves, Granada, Spain 3Genomic Oncology Area, GENYO, Centre for Genomics an...
متن کاملVaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.
PURPOSE A multiple myeloma vaccine has been developed whereby patient-derived tumor cells are fused with autologous dendritic cells, creating a hybridoma that stimulates a broad antitumor response. We report on the results of a phase II trial in which patients underwent vaccination following autologous stem cell transplantation (ASCT) to target minimal residual disease. EXPERIMENTAL DESIGN Tw...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Patient Experience
سال: 2021
ISSN: 2374-3735,2374-3743
DOI: 10.1177/2374373521998864